Info

Trubion Pharmaceuticals, Inc. (Trubion) is a biopharmaceutical company creating a pipeline of protein therapeutic product candidates to treat autoimmune and inflammatory diseases, and cancer. The Company’s product candidates are small modular immunopharmaceuticals or SMIP, therapeutics and are designed using its custom drug assembly technology. TRU-015, the Company’s principal product, has completed a Phase IIb clinical trial for the treatment of rheumatoid arthritis (RA). Its TRU-016 product candidate is a CD37- targeted therapy for the treatment of B-cell malignancies, such as chronic lymphocytic leukemia (CLL), and non-Hodgkin’s lymphoma (NHL). Trubion filed an Investigational New Drug application (IND), for its TRU-016 product candidate for the treatment of B-cell malignancies in as of December 31, 2007.(Source: 10-K)